AXL and COVID-19: In this context, it is interesting to note that the AXL inhibitor Bemcentinib (BGB324), currently undergoing Phase II clinical trials for several cancer types, has been fast-tracked towards Phase II clinical trials by the UK government-funded ACCORD (Accelerating Covid-19 Research & Development platform) study, while other AXL inhibitors have been proposed as possible treatments for COVID-19 [106].